A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses

Journal of Infectious Diseases

Volumn 210, Issue 8, 2014, Pages 1260-1269

  Escuret, Vanessa ^a,c   Collins, Patrick J ^e   Casalegno, Jean Sébastien ^a,c   Vachieri, Sebastien G ^e,f   Cattle, Nicholas ^g   Ferraris, Olivier ^c   Sabatier, Murielle ^c   Frobert, Emilie ^a,c   Caro, Valérie ^d   Skehel, John J ^e   Gamblin, Steve ^f   Valla, Frédéric ^b   Valette, Martine ^a   Ottmann, Michèle ^c   McCauley, John W ^g   Daniels, Rodney S ^g   Lina, Bruno ^a,c  

^a Hospices Civils de Lyon   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d INSTITUT PASTEUR   (France)

^e Division of Virology   (United Kingdom)

^f Division of Molecular Structure   (United States)

^g NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Influenza B virus; Neuraminidase substitution I221L; Oseltamivir resistance

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; CORTICOSTEROID; ENZYME VARIANT; IMMUNOGLOBULIN; INFLUENZA VACCINE; ISOLEUCINE; LEUCINE; MYCOPHENOLIC ACID; OSELTAMIVIR; TACROLIMUS; VIRUS SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; HEMAGGLUTININ; SIALIDASE;

ADOLESCENT; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL TISSUE; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME STRUCTURE; GENE MUTATION; GENE STRUCTURE; GROWTH RATE; HETEROZYGOTE; HUMAN; HYDROPHOBICITY; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; INFLUENZA B; INFLUENZA B VIRUS; MALE; MDCK CELL LINE; NEURAMINIDASE GENE; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS GENE; VIRUS ISOLATION; ANIMAL; CASE REPORT; CELL LINE; DOG; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; INFLUENZA VIRUS B; METABOLISM; NEURAMINIDASE SUBSTITUTION I221L; OSELTAMIVIR RESISTANCE; VIRUS CULTURE;

INFLUENZA B VIRUS; NEURAMINIDASE SUBSTITUTION I221L; OSELTAMIVIR RESISTANCE;

ADOLESCENT; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; DRUG RESISTANCE, VIRAL; GENE EXPRESSION REGULATION, VIRAL; HEMAGGLUTININS; HUMANS; INFLUENZA B VIRUS; MALE; NEURAMINIDASE; OSELTAMIVIR; VIRAL PLAQUE ASSAY;

EID: 84909992797     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu244     Document Type: Article

References (48)

1. Klimov AI, Garten R, Russell C, et al. WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A (H1N1) pdm09, A (H3N2) and B influenza viruses collected from February to September 2011. Vaccine 2012;30:6461-71.
2. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009;15:552-60.
3. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004;103:199-203.
4. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviralresistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005;49:4515-20.
5. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008;41:13-9.
6. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983;303:41-4.
7. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993;67:2972-80.
8. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006;443:45-9.
9. (CDC) Cf DCa P. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009;58:969-72.
10. Baz M, Abed Y, McDonald J, Boivin G. Characterization of multidrugresistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006;43:1555-61.
11. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006;193:760-4.
12. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 2010;54:1834-41.
13. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998;178:1257-62.
14. Escuret V, Frobert E, Bouscambert-Duchamp M, et al. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 2008;41:25-8.
15. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. Jama 2007;297:1435-42.
16. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006;50:2395-402.
17. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008;52:3284-92.
18. Sleeman K, Sheu TG, Moore Z, et al. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerg Infect Dis 2011;17:2043-6.
19. Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 2005;68:43-8.
20. WHO Nal. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 2012;87:369-74.
21. Casalegno JS, Bouscambert-Duchamp M, Caro V, et al. Oseltamivirresistant influenza A (H1N1) viruses in south of France, 2007/2009. Antiviral Res 2010;87:242-8.
22. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493-7.
23. Escuret V, Cornu C, Boutitie F, et al. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A (H1N1) virus infections. Antiviral Res 2012;96:130-7.
24. Burmeister WP, Daniels RS, Dayan S, Gagnon J, Cusack S, Ruigrok RW. Sequence and crystallization of influenza virus B/Beijing/1/87 neuraminidase. Virology 1991;180:266-72.
25. Kabsch W. XDS. Acta Crystallogr D Biol Crystallogr 2010;66:125-32.
26. Winn MD, Ballard CC, Cowtan KD, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 2011;67:235-42.
27. Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 2006;62:72-82.
28. Evans PR, Murshudov GN. Acta Crystallogr. D Biol Crystallogr 2013;69:1204-14.
29. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr 2007;40:658-74.
30. Emsley P, Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60:2126-32.
31. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997;53:240-55.
32. Adams PD, Afonine PV, Bunkoczi G, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 2010;66:213-21.
33. Terwilliger TC, Grosse-Kunstleve RW, Afonine PV, et al. Iterative model building, structure refinement and density modification with PHENIX AutoBuild wizard. Acta Crystallogr D Biol Crystallogr 2008;64:61-9.
34. Chen VB, Arendall WB III, Headd JJ, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 2010;66:12-21.
35. Pozo F, Lina B, Andrade HR, et al. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. J Clin Virol 2013;57:5-12.
36. Wargo AR, Kurath G Viral fitness: definitions, measurement, and current insights. Curr Opin Virol 2012;2:538-45.
37. Garg S, Moore Z, Lee N, et al. A cluster of patients infected with I221V influenza b virus variants with reduced oseltamivir susceptibility-North Carolina and South Carolina, 2010-2011. J Infect Dis 2013;207:966-73.
38. Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob Agents Chemother 2009;53:3088-96.
39. McKimm-Breschkin JL, Barrett S, Pudjiatmoko, et al. I222 Neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian Clade 2.1 highly pathogenic Avian Influenza A (H5N1) viruses. PLoS One 2013;8:e66105.
40. Hurt AC, Holien JK, Barr IG In vitro generation of neuraminidase inhibitor resistance in A (H5N1) influenza viruses. Antimicrob Agents Chemother 2009;53:4433-40.
41. Boltz DA, Douangngeun B, Phommachanh P, et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao People's Democratic Republic. J Gen Virol 2010;91:949-59.
42. Govorkova EA, Ilyushina NA, Marathe BM, McClaren JL, Webster RG. Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model. J Virol 2010;84:8042-50.
43. Van Der Vries E, Stelma FF, Boucher CA. Emergence of a multidrugresistant pandemic influenza A (H1N1) virus. N Engl J Med 2010;363:1381-2.
44. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010;51:983-4.
45. Le Goff J, Rousset D, Abou-Jaoude G, et al. I223R mutation in influenza A (H1N1) pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y. PLoS One 2012;7:e37095.
46. Pizzorno A, Bouhy X, Abed Y, Boivin G Generation and characterization of recombinant pandemic influenza A (H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis 2011;203:25-31.
47. Richard M, Ferraris O, Erny A, et al. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob Agents Chemother 2011;55:2942-52.
48. Kurowski M, Oo C, Wiltshire H, Barrett J. Oseltamivir distributes to influenza replication sites in the middle ear and sinuses. Clin Drug Investig 2004;24:49-53.